Cargando…

PEPT1-mediated prodrug strategy for oral delivery of peramivir

Peramivir was a novel and highly potent neuraminidase (NA) inhibitor for the treatment of influenza A and B. However, it exhibited a very low oral bioavailability (only 3%) due to the high polarity (log P of −1.4) and the low membrane permeability across the intestine. To utilize the PEPT1-mediated...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yongbing, Gan, Wei, Lei, Mingdao, Jiang, Wei, Cheng, Meng, He, Junwei, Sun, Qi, Liu, Wan, Hu, Lvjiang, Jin, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032255/
https://www.ncbi.nlm.nih.gov/pubmed/32104429
http://dx.doi.org/10.1016/j.ajps.2018.05.008
_version_ 1783499538425708544
author Sun, Yongbing
Gan, Wei
Lei, Mingdao
Jiang, Wei
Cheng, Meng
He, Junwei
Sun, Qi
Liu, Wan
Hu, Lvjiang
Jin, Yi
author_facet Sun, Yongbing
Gan, Wei
Lei, Mingdao
Jiang, Wei
Cheng, Meng
He, Junwei
Sun, Qi
Liu, Wan
Hu, Lvjiang
Jin, Yi
author_sort Sun, Yongbing
collection PubMed
description Peramivir was a novel and highly potent neuraminidase (NA) inhibitor for the treatment of influenza A and B. However, it exhibited a very low oral bioavailability (only 3%) due to the high polarity (log P of −1.4) and the low membrane permeability across the intestine. To utilize the PEPT1-mediated prodrug strategy to improve the oral absorption and develop the oral alternative, seven amino acid ester prodrugs and seven amino acid amide prodrugs have been synthesized. The permeability of these prodrugs across Caco-2 cells were screened. Peramivr-(CH(2))(2)-l-Val and Peramivir-l-Ile were of the highest permeability in ester prodrugs and amide prodrugs, respectively, and then they were selected for further studies. Glycylsarcosine (gly-sar) uptake by Caco-2 could be inbihited by Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile in a concentration-dependent manner, and the IC(50) was 1.34 ± 0.31 mM and 1.78 ± 0.48 mM, respectively. The direct uptake of Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile in MDCK-PEPT1 cells were significantly higher than in MDCK mock cells, and could be markedly inhibited by gly-sar. The uptake of Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile (0.01 to 50 mM) in MDCK-hPEPT1 cells conformed to Michaelis–Menten Equation. The oral bioavailability of peramivir was 65.3% and 37.3% after the oral administration of Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile to rats, respectively. The oral absorption and bioactivation of Peramivir-(CH(2))(2)-l-Val was rapid and extensive, and no Peramivir-(CH(2))(2)-l-Val was found in plasma. Because the amide bond was relatively stable, Peramivir-l-Ile could not be totally converted to the parent drug in vivo. Peramivir-(CH(2))(2)-l-Val with good oral profiles and rapid bioactivation might be a promising prodrug for the further clinic development. The present study also corroborated the idea that the PEPT1-mediated prodrug approach has enormous promise for improving the oral absorption of poorly absorbed drug.
format Online
Article
Text
id pubmed-7032255
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Shenyang Pharmaceutical University
record_format MEDLINE/PubMed
spelling pubmed-70322552020-02-26 PEPT1-mediated prodrug strategy for oral delivery of peramivir Sun, Yongbing Gan, Wei Lei, Mingdao Jiang, Wei Cheng, Meng He, Junwei Sun, Qi Liu, Wan Hu, Lvjiang Jin, Yi Asian J Pharm Sci Research Paper Peramivir was a novel and highly potent neuraminidase (NA) inhibitor for the treatment of influenza A and B. However, it exhibited a very low oral bioavailability (only 3%) due to the high polarity (log P of −1.4) and the low membrane permeability across the intestine. To utilize the PEPT1-mediated prodrug strategy to improve the oral absorption and develop the oral alternative, seven amino acid ester prodrugs and seven amino acid amide prodrugs have been synthesized. The permeability of these prodrugs across Caco-2 cells were screened. Peramivr-(CH(2))(2)-l-Val and Peramivir-l-Ile were of the highest permeability in ester prodrugs and amide prodrugs, respectively, and then they were selected for further studies. Glycylsarcosine (gly-sar) uptake by Caco-2 could be inbihited by Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile in a concentration-dependent manner, and the IC(50) was 1.34 ± 0.31 mM and 1.78 ± 0.48 mM, respectively. The direct uptake of Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile in MDCK-PEPT1 cells were significantly higher than in MDCK mock cells, and could be markedly inhibited by gly-sar. The uptake of Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile (0.01 to 50 mM) in MDCK-hPEPT1 cells conformed to Michaelis–Menten Equation. The oral bioavailability of peramivir was 65.3% and 37.3% after the oral administration of Peramivir-(CH(2))(2)-l-Val and Peramivir-l-Ile to rats, respectively. The oral absorption and bioactivation of Peramivir-(CH(2))(2)-l-Val was rapid and extensive, and no Peramivir-(CH(2))(2)-l-Val was found in plasma. Because the amide bond was relatively stable, Peramivir-l-Ile could not be totally converted to the parent drug in vivo. Peramivir-(CH(2))(2)-l-Val with good oral profiles and rapid bioactivation might be a promising prodrug for the further clinic development. The present study also corroborated the idea that the PEPT1-mediated prodrug approach has enormous promise for improving the oral absorption of poorly absorbed drug. Shenyang Pharmaceutical University 2018-11 2018-10-03 /pmc/articles/PMC7032255/ /pubmed/32104429 http://dx.doi.org/10.1016/j.ajps.2018.05.008 Text en © 2018 Shenyang Pharmaceutical University. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Sun, Yongbing
Gan, Wei
Lei, Mingdao
Jiang, Wei
Cheng, Meng
He, Junwei
Sun, Qi
Liu, Wan
Hu, Lvjiang
Jin, Yi
PEPT1-mediated prodrug strategy for oral delivery of peramivir
title PEPT1-mediated prodrug strategy for oral delivery of peramivir
title_full PEPT1-mediated prodrug strategy for oral delivery of peramivir
title_fullStr PEPT1-mediated prodrug strategy for oral delivery of peramivir
title_full_unstemmed PEPT1-mediated prodrug strategy for oral delivery of peramivir
title_short PEPT1-mediated prodrug strategy for oral delivery of peramivir
title_sort pept1-mediated prodrug strategy for oral delivery of peramivir
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032255/
https://www.ncbi.nlm.nih.gov/pubmed/32104429
http://dx.doi.org/10.1016/j.ajps.2018.05.008
work_keys_str_mv AT sunyongbing pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT ganwei pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT leimingdao pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT jiangwei pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT chengmeng pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT hejunwei pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT sunqi pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT liuwan pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT hulvjiang pept1mediatedprodrugstrategyfororaldeliveryofperamivir
AT jinyi pept1mediatedprodrugstrategyfororaldeliveryofperamivir